LCTX vs JSPR โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
JSPR Captures Institutional Edge (3โ1 Pillars ยท 3โ7 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Jasper Therapeutics, Inc. Common Stock (JSPR) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while LCTX counters with relative strength in Valuation. Fundamentally, LCTX trades at 30.7x Forward P/E with -280.3% operating margin (-61.0% YoY revenue) versus JSPR at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, LCTX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro) against JSPR sits in UNCLASSIFIED (45th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | LCTX | JSPR | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $212.1M | $12.8M | Larger Scale | LCTX |
| Trailing P/E Ratio Valuation | 30.7x | N/M | Lower Multiple | LCTX |
| Forward P/E Ratio Valuation | 30.7x | N/M | Lower Multiple | LCTX |
| Revenue Growth (YoY) Growth | -61.0% | +0.0% | Higher Growth | JSPR |
| Operating Margin (TTM) Profitability | -280.3% | 0.0% | Higher Margin | JSPR |
| Net Profit Margin Profitability | 16.2% | 0.0% | Higher Margin | LCTX |
| Return on Equity (ROE) Capital Efficiency | 4.3% | -255.1% | Higher ROE | LCTX |
| 52-Week Range Position Momentum | 4% ($1โ$2) | 62% ($0โ$17) | Stronger Trend | JSPR |
| Beta / 30D Volatility Risk Regime | 1.36ฮฒ ยท 79% Vol | 8.00ฮฒ ยท 11818% Vol | Lower Realized Risk | LCTX |
| Unified Institutional Score Composite Signal | 58.9 / 100 (HOLD) | 33.8 / 100 (SELL) | Higher Composite | LCTX |